New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 30, 2013
08:38 EDTBGMDBG Medicine announces preliminary decision by CMS on BGM Galectin-3 test
BG Medicine announced that the Centers for Medicare and Medicaid Services, or CMS, have made a preliminary decision to set the Medicare payment rate for the Company's BGM Galectin-3 test at the amount of a cross walked test whose 2013 national limitation amount is $30.24, subject to a final determination by CMS by year-end 2013. The new payment rate, if finalized, will replace the BGM Galectin-3 test's national limitation amount of $17.80 that was effective in 2013. This preliminary determination by CMS comes in response to BG Medicine's request for reconsideration of the 2013 CMS determination. The BGM Galectin-3 test is a novel test, which is cleared by the FDA as an aid in assessing the prognosis of patients with chronic heart failure.
News For BGMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 13, 2014
10:57 EDTBGMDBG Medicine downgraded to Neutral from Buy at Ladenburg
Ladenburg downgraded BG Medicine to Neutral citing valuation following the company's Q3 results.
06:33 EDTBGMDBG Medicine sees 2014 revenue $2.8M-$3.0M, one estimate $3.10M
Subscribe for More Information
06:32 EDTBGMDBG Medicine reports Q3 EPS (7c), one estimate (7c)
Reports Q3 revenue $695K, one estimate $800.00K.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use